Generic Lidoderm 5% Patch Launches

Actavis Pharma, Inc. has launched generic Lidoderm® (lidocaine patch 5%), which received FDA approval on August 23, 2012. Inventory will begin arriving in distribution centers on Monday, September 16.

Lidoderm (lidocaine patch 5%) is used to relieve the pain of post-herpetic neuralgia, also referred to as after-shingles pain. Estimated U.S. annual brand sales for this product are $1.3B.

Actavis is exclusive in the market for this new generic, with 180-day exclusivity lasting until March 14, 2014.